Abstract
In a small trial involving children with progressive high-grade gliomas, direct infusions of a genetically engineered strain of herpes simplex virus elicited responses in 11 of 12 recipients. The therapy also led to more than a doubling in average patient survival compared with historical expectations.
©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.